Zhitong Finance App News, ST Renfu (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently received the “Drug Registration Certificate” for carbamazepine sustained-release tablets (II) approved and issued by the State Drug Administration. Carbamazepine sustained-release tablets (II) are mainly used to treat seizures, including partial seizures, primary or secondary generalized tonic-clonic seizures, and mixed seizures; to relieve trigeminal neuralgia, including trigeminal neuralgia due to multiple sclerosis, primary trigeminal neuralgia, and primary glossopharyngeal neuralgia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.